VITRAKVI (larotractenib) oral solution, 20mg/mL, 100 mL bottle, Rx only, Manufactured for Bayer H...
FDA Drug Recall #D-0145-2024 — Class I — November 6, 2023
Recall Summary
| Recall Number | D-0145-2024 |
| Classification | Class I — Serious risk |
| Date Initiated | November 6, 2023 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Bayer Healthcare Pharmaceuticals Inc. |
| Location | Whippany, NJ |
| Product Type | Drugs |
| Quantity | 192 bottles |
Product Description
VITRAKVI (larotractenib) oral solution, 20mg/mL, 100 mL bottle, Rx only, Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981. NDC 50419-392-01
Reason for Recall
Microbial Contamination of Non-Sterile Products: microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing
Distribution Pattern
Product was distributed to specialty pharmacies and distributors nationwide who may have further distributed the product.
Lot / Code Information
Lot# 2114228, EXP. 02/29/2024
Other Recalls from Bayer Healthcare Pharmaceuticals Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0248-2022 | Class I | LOTRIMIN AF, (Miconazole nitrate 2%), Powder Sp... | Oct 1, 2021 |
| D-0236-2022 | Class II | LOTRIMIN AF (Miconazole nitrate 2%) Deodorant P... | Oct 1, 2021 |
| D-0253-2022 | Class I | Tinactin (Tolnaftate 1%) POWDER SPRAY NET WT 13... | Oct 1, 2021 |
| D-0251-2022 | Class I | Tinactin (Tolnaftate 1%) LIQUID SPRAY NET WT150... | Oct 1, 2021 |
| D-0242-2022 | Class II | Tinactin (Tolnaftate 1%) DEODORANT POWDER SPRAY... | Oct 1, 2021 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.